Work

Comparison of the effects of Propofol, Dexmedetomidine and Midazolam on Sedation and Oxidative-Antioxidant System in Critically ill Patients

Year: 2022

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: Background: This study aimed to compare the impact of midazolam, propofol, dexmedetomidine infusions for 24th hour on total antioxidant status (TAS), total oxidant status (TOS), oxidative stres index (OSI) and prolidase levels. Material and Method: 75 patient ICU patient who were mechanically ventilated enrolled to the study. Patients randomised to three groups. Group I (n=25, midazolam): 0.02 mg/ kg/h midazolam, Group II (n = 25, propofol): 1mg/kg/h propofol, Group III (n=25, dexmedetomidine): 0.2 µg/ kg/h dexmedetomidine infusions was started. Dosage were arrange to achieve Ramsay sedation score 3. Blood samples were collected in basal, 6.,12.,18., 24. hour, and hemodynamic parameters were also recorded in the same time intervals. Results: In midazolam group 24. hour TAS levels were significantly decreased and TOS, prolidase and OSI levels were significantly increased compared to the basal level (p<0.05). 24. hour TAS levels were significantly decreased and TOS, prolidase and OSI levels were significantly increased compared to basal level in propofol group (p<0,05). In dexmedotimidine groups 24.hour TAS and prolidase levels were significantly decreased, OSI levels were increased compared to the basal levels (p<0.05). Increase in TOS levels were not statistically significant (p>0.05). Basal TAS, TOS, prolidase, OSI levels were not statistically significantly between the different groups (p>0.05).Conclusion: This study showed that there were no statistically significant differences between the groups. Among hemodynamic parameters Dexmedetomidine was found to be having statistically significant favorable results in comparison to others. However there results should be clinically and molecularity verified with large scale further studies.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.7239283